Parsonage–Turner syndrome following COVID-19 vaccine

Sharma, Rajaram; Dua, Bhumika; Goyal, Saurabh; Tiwari, Tapendra

doi:10.4103/aian.aian_354_22

Cited by 6 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This systematic review included 30 articles [ 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 ] and 10 meeting abstracts [ 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 ] reporting on 59 cases. Among them, 36 (61.0%) patients received a mRNA vaccine (24 with BNT162b2, Pfizer, 10 with mRNA-1273, Moderna) [ 22 , 24 , 25 , 26 , 27 , 29 , 30 , 34 , 36 , 37 , 38 , 39 , 40 , 41 , …”

Section: Resultsmentioning

confidence: 99%

“…In patients receiving mRNA vaccines, authors reported decreased motor unit recruitment [ 22 , 37 , 40 , 41 ], abnormal spontaneous activity [ 56 ], acute-to-subacute brachial plexopathy [ 25 ], fibrillations and positive sharp waves [ 26 , 50 ], chronic neuropathic changes [ 27 ], and normal findings [ 34 ]. In the other group, the EMG revealed acute denervation signs [ 23 , 42 , 43 ], fibrillations and positive waves [ 28 , 31 ], decreased motor unit recruitment [ 39 ], and reinnervation signs [ 23 , 44 ].…”

Section: Resultsmentioning

confidence: 99%

“…In both groups, the patients were prescribed various regimens, including corticosteroids [ 22 , 24 , 25 , 26 , 28 , 29 , 30 , 33 , 34 , 36 , 37 , 38 , 39 , 41 , 48 , 50 , 53 , 56 , 60 ], nonsteroidal anti-inflammatory drugs (NSAIDs) [ 25 , 33 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 49 ], Pregabalin [ 26 , 39 , 44 , 48 ], Gabapentin [ 24 , 41 , 50 ], and acetaminophen [ 44 , 53 ]. In addition, in the mRNA group, one patient (2.9%) received intravenous immunoglobulin [ 46 ], two were prescribed tricyclic antidepressants (5.7%) [ 39 , 48 ], and four (11.4%) received opiates [ 39 , 48 , 53 , 60 ].…”

Section: Resultsmentioning

confidence: 99%

“…In most cases, further PTS symptoms appeared within two weeks after the onset of pain; only two patients with a history of viral vector vaccination presented motor and sensory signs after three weeks [ 42 ] and one month, respectively [ 44 ]. These findings contrast the data from the literature, including patients with or without COVID-19, where authors found that in 27.2% [ 1 ] and 25% [ 62 ] of cases, paresis did not manifest itself until over two weeks later [ 1 ].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Parsonage–Turner Syndrome following COVID-19 Vaccination: A Systematic Review

Rosca,

Al-Qiami,

Cornea

et al. 2024

Vaccines

View full text Add to dashboard Cite

Background: Parsonage–Turner syndrome (PTS) is an inflammatory condition of the brachial plexus, with more than half of patients presenting a trigger, such as infection or vaccination. Our objective was to synthesize the clinical and paraclinical features, therapeutic responses, and outcomes of PTS post-COVID-19 vaccination. Methods: We systematically reviewed two databases (LitCOVID and the WHO database on COVID-19) up to January 2024 following a published protocol (OSF registries). Results: We included 59 cases. PTS occurred more frequently in males (61.1% mRNA group, 83.3% viral vector group). Patients in the mRNA group were younger (41.7% between 41 and 50 years vs. 38.9% between 61 and 70 years). Most cases had sudden pain within two weeks. Unilateral PTS was present in 94.4% of mRNA and all viral vector-vaccinated cases. Symptoms included pain (97.1% and 92.3%, respectively), usually followed within two weeks by motor deficits (97.2% and 94.1%, respectively), amyotrophy (30% and 81.8%, respectively), paresthesia (50% and 27.3%, respectively), and sensory loss (33.3% and 38.5%, respectively). Viral vector vaccine recipients had nerve involvement outside the brachial plexus. Ancillary investigations revealed CSF albuminocytological dissociation (33.3% and 100%, respectively) and ipsilateral axillary lymphadenopathy. Two PTS cases worsened after the second mRNA dose, and another recurred after influenza vaccination. One patient well tolerated the second dose of the viral vector vaccine, but symptoms reemerged in another. Conclusions: Current evidence suggests PTS may occur after all COVID-19 vaccine types, with some subgroup differences. Also, PTS might recur with subsequent similar or unrelated vaccines.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Parsonage–Turner Syndrome following COVID-19 Vaccination: A Systematic Review

Rosca,

Al-Qiami,

Cornea

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…We would like to share ideas on the publication “Parsonage–Turner syndrome following COVID-19 vaccine.”[ 1 ] An intriguing example described by Sharma et al . [ 1 ] stated that, while this article depicts one of the few, if not the first, instances of Parsonage–Turner Syndrome (PTS) following COVID-19 vaccination in India, medical professionals in that country should take these sequelae into account when treating brachial neuritis cases. It is frequently challenging to pinpoint the precise clinical connection because there is little clinical information on the health and immunological status of vaccination recipients prior to injection.…”

mentioning

confidence: 99%